Neuroimaging trials of Parkinson’s disease progression

被引：1
|
作者：
John Seibyl
Danna Jennings
Rowena Tabamo
Ken Marek
机构：
[1] Institute for Neurodegenerative Disorders,
[2] IND,undefined
[3] Institute for Neurodegenerative Disorders,undefined
来源：
Journal of Neurology | 2004年 / 251卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：vii9 / vii13
相关论文
共 50 条
  • [31] Neuroimaging of serotonergic parameters in Parkinson's disease
    Bruecke, T.
    Holler, I.
    Bencsits, G.
    Berding, G.
    Asenbaum, S.
    Pirker, W.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 299 - 299
  • [32] Neuroimaging of depression in Parkinson's disease: a review
    Chagas, Marcos Hortes N.
    Linares, Ila M. P.
    Garcia, Giovana Jorge
    Hallak, Jaime E. C.
    Tumas, Vitor
    Crippa, Jose Alexandre S.
    INTERNATIONAL PSYCHOGERIATRICS, 2013, 25 (12) : 1953 - 1961
  • [33] Editorial: Neuroimaging in Parkinson's disease and Parkinsonism
    Zhang, Yu
    Tartaglia, Maria Carmela
    Zhan, Wang
    Ofori, Edward
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [34] Neuroimaging in Parkinson's Disease: necessity or exaggeration?
    Smilowska, Katarzyna
    Burzynska-Makuch, Malgorzata
    Brockhuis, Bogna
    Piekarski, Radoslaw
    Friedman, Andrzej
    Popek, Aleksandra
    Slawek, Jaroslaw
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2021, 55 (06) : 536 - 548
  • [35] Neuroimaging of Parkinson's disease: Expanding views
    Weingarten, Carol P.
    Sundman, Mark H.
    Hickey, Patrick
    Chen, Nan-kuei
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2015, 59 : 16 - 52
  • [36] Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
    Veitch, Dallas P.
    Weiner, Michael W.
    Aisen, Paul S.
    Beckett, Laurel A.
    Cairns, Nigel J.
    Green, Robert C.
    Harvey, Danielle
    Jack, Clifford R., Jr.
    Jagust, William
    Morris, John C.
    Petersen, Ronald C.
    Saykin, Andrew J.
    Shaw, Leslie M.
    Toga, Arthur W.
    Trojanowski, John Q.
    Aisen, Paul
    Weiner, Michael
    Petersen, Ronald
    Trojanowki, John Q.
    Toga, Arthur W.
    Beckett, Laurel
    Morris, John
    Khachaturian, Zaven
    Sorensen, Greg
    Carrillo, Maria
    Kuller, Lew
    Raichle, Marc
    Paul, Steven
    Davies, Peter
    Fillit, Howard
    Hefti, Franz
    Holtzman, David
    Mesulam, M. Marcel
    Potter, William
    Snyder, Peter
    Montine, Tom
    Jimenez, Gustavo
    Donohue, Michael
    Gessert, Devon
    Harless, Kelly
    Salazar, Jennifer
    Cabrera, Yuliana
    Walter, Sarah
    Hergesheimer, Lindsey
    Harvey, Danielle
    Bernstein, Matthew
    Fox, Nick
    Thompson, Paul
    Schuff, Norbert
    DeCArli, Charles
    ALZHEIMERS & DEMENTIA, 2019, 15 (01) : 106 - 152
  • [37] The Parkinson's progression marker initiative (PPMI) - Developing a sample size estimate for Parkinson's disease therapeutic trials
    MOVEMENT DISORDERS, 2015, 30 : S428 - S429
  • [38] Beyond Clinical Presentation: Incorporating Neuroimaging and Biofluid Markers to Predict Progression of Parkinson's disease (PD)
    Collins-Praino, L.
    McNamara, A.
    Ellul, B.
    Baetu, I.
    Lau, S.
    Jenkinson, M.
    MOVEMENT DISORDERS, 2024, 39 : S63 - S64
  • [39] Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease
    Romero, Klaus
    Conrado, Daniela
    Burton, Jackson
    Nicholas, Timothy
    Sinha, Vikram
    Macha, Sreeraj
    Ahamadi, Malidi
    Cedarbaum, Jesse
    Seibyl, John
    Marek, Kenneth
    Basseches, Peter
    Hill, Derek
    Somer, Ed
    Gallagher, Jill
    Dexter, David T.
    Roach, Arthur
    Stephenson, Diane
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (03): : 240 - 246
  • [40] Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studies
    Marek, K
    Jennings, D
    Seibyl, J
    ANNALS OF NEUROLOGY, 2003, 53 : S160 - S166
12345